



QUARTERLY COMPLIANCE REPORT ON CORPORATE GOVERNANCE

Name of the Company: GlaxoSmithKline Consumer Healthcare Limited

Quarter ending on: December 31, 2013

Particulars	Clause of Listing agreement	Compliance Status Yes/No	Remarks
I. Board of Directors	49 I		
(A) Composition of Board	49(IA)	Yes	
(B) Non-executive Directors' compensation & disclosure	49 (IB)	Yes	
(C) Other provisions as to Board and Committees	49 (IC)	Yes	
(D) Code of Conduct	49 (ID)	Yes	Affirmation of compliance with the Code of Conduct for the year ending March 31, 2014 will be obtained in April 2014.
II. Audit Committee	49 (II)		
(A) Qualified & Independent Audit Committee	49 (IIA)	Yes	
(B) Meeting of Audit Committee	49 (IIB)	Yes	
(C) Powers of Audit Committee	49 (IIC)	Yes	
(D) Role of Audit Committee	49 II(D)	Yes	
(E) Review of Information by Audit Committee	49 (IIE)	Yes	
III. Subsidiary Companies	49 (III)	N.A.	
IV. Disclosures	49 (IV)		
(A) Basis of related party transactions	49 (IV A)	Yes	
(B) Disclosure of Accounting Treatment	49 (IV B)	N.A.	
(C) Board Disclosures	49 (IV C)	Yes	
(D) Proceeds from public issues, rights issues, preferential issues etc.	49 (IV D)	N.A.	
(E) Remuneration of Directors	49 (IV E)	Yes	Relevant disclosures will be made in the Corporate Governance report forming part of the Annual Report for the year ended March 31, 2014.
(F) Management	49 (IV F)	Yes	Management Discussion and Analysis report will form part of the Annual Report for the year ended March 31, 2014.
(G) Shareholders	49 (IV G)	Yes	
V.CEO/CFO Certification	49 (V)	Yes	CEO/CFO Certification will be obtained and form part of the Annual Report for the year ended March 31, 2014.
VI. Report on Corporate Governance	49 (VI)	Yes	Corporate Governance Report will form part of the Annual Report for the year ended March 31, 2014.
VII. Compliance	49 (VII)	Yes	Certificate regarding Compliance will form part of the Directors report for the year ending March 31, 2014. Disclosures of the compliance with mandatory requirements and adoption of the non-mandatory requirements will be made in the corporate governance report for the year ended March 31, 2014.